ArticleNature biomedical engineering2026
Off‑the‑shelf, engineered non-living stem cell strategy for advancing cellular therapies.
Article in Nature biomedical engineering, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Non-living cell therapeutics have become crucial for treating diverse disease conditions. However, ineffective manufacturing processes, significant cellular content loss and structural damage reduce therapeutic efficacy. Here we present a translational approach for designing 'off-the-shelf' highly efficient active lyophilized tannic-acid-engineered non-living cells (HealTEC) with distinct features. Our strategy is customizable and integrates cellular function enhancement, high-dose tannic acid-induced cell inactivation, low-temperature cellular matter condensation and advanced lyophilization. By leveraging it, we engineer mesenchymal stem cell-derived HealTEC as a bio-reservoir platform, enabling formulations enriched in immunomodulatory factors for ulcerative colitis, enriched in angiogenic factors for hindlimb ischaemia or loaded with drug nanoparticles for asthma. Importantly, the HealTEC formulations exhibit high therapeutic stability after long-term storage at mild conditions. Furthermore, HealTEC injections induce much lower immunogenicity than living cell injections, both in the short term and long term. HealTEC technology presents the potential for upscaling cell manufacture, commercialization and reshaping worldwide clinical demands.
Identifiers
42373801What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.